BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
» Regulatory actions for Nov. 4, 2021
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Regulatory actions for Nov. 4, 2021
Nov. 4, 2021
No Comments
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Allena, Astrazeneca, BMS, Biontech, Daiichi, Inovio, Effrx, Enlivex, Epizyme, Innovent, Inovio, Kangtai, Lipocine, Macrogenics, Menarini, Merck, Merus, Minerva, Neurona, Novavax, Ocugen, OS, Pfizer, Rafael, Ridgeback, Transthera, Union, Y-mabs.
BioWorld
Briefs
Regulatory
Regulatory actions
Coronavirus